Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-01-19
2001-04-03
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S075000
Reexamination Certificate
active
06211230
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates in general to reducing brain damage resulting from seizures and in particular to reducing brain damage resulting from seizures caused by nerve agents.
One aspect of chemical warfare involves exposing the enemy to nerve agents. The best defense to nerve agent exposure is, of course, to prevent the soldier from being exposed to the nerve agent. However, exposure to nerve agents may occur and must be treated. Certain nerve agents cause seizures. Examples of organophosphorus nerve agents that cause seizures are GB (sarin), GD (soman), GA (tabun) and GF. It cannot be certain that every victim on the chemical battlefield will receive the fielded therapy regimen (atropine, 2-PAM, diazepam) within the prescribed window of opportunity. These victims may experience prolonged seizure episodes lasting one or more hours. Availability of a drug that will stop development of the lesions after prolonged seizure epilectus would be a valuable adjunct to the current therapeutic regimens.
Throughout the specification, certain publications are identified parenthetically by author and date. A complete identification of these publications is given at the end of the specification. The publication entitled “Neuroprotective Effects of HU-211 on Brain Damage Resulting from Soman-induced Seizures” by Filbert, M. G.; Forster, J. S.; Smith, C. D.; Ballough, G. P.; Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, Oct. 1998, is hereby expressly incorporated by reference. Exposure to high concentrations of the nerve agent soman (pinacolylymethylphosphonofluoridate), an organophosphorus (OP) inhibitor of cholinesterases, leads to the development of seizures (Taylor, 1985) and brain damage (Shih and McDonough, 1997; Ballough el al. 1998). Seizure-related brain damage (SRBD) resulting from exposure to soman is considered to be excitotoxic (Olney et al., 1983). Soman-induced seizures are initiated by the high levels of acetylcholine that accumulate as a result of the irreversible inhibition of acetylcholinesterase (AChE). As the duration of seizures increases, excitatory amino acids released by elevated levels of acetylcholine assume control over the seizures and are maintained by this neurotransmitter system (Shih and McDonough, 1997; Olney et al., 1983; Sparenborg et al., 1992). This conclusion is supported by studies demonstrating that soman-induced seizures and the resulting brain damage can be ameliorated by administration of antagonists of N-methyl-D-aspartate (NMDA) such as MK-801 (Braitman and Sparenborg, 1989; Clifford et al., 1989, 1990). Because MK-801 produces neurotoxic effects (Fix et al., 1993), it is not likely to be useful clinically. Therefore, a need exists for a clinically useful neuroprotectant to reduce brain damage caused by organophosphorus nerve agent-induced seizures.
HU-211 (dexanabinol, (+)-(3S,4S)-7-hydroxy-&Dgr;-6 tetrahydro cannabinol 1,1 dimethylheptyl) is a nonpsychotropic cannabinoid that has been shown to have neuroprotectant effects in neurons exposed to excitotoxins in culture (Eshhar et al., 1993, 1995). HU-211 antagonizes glutamatergic neurotransmission in the brain and also inhibits metabolic events that lead to neuronal degeneration (Biegon and Bar Joseph, 1995; Shohami et al., 1997). In addition to having NMDA-blocking activity, HU-211 appears to act as a potent scavenger of peroxy and hydroxy radicals (Shohami et al., 1997) and to reduce the destabilization of calcium homeostasis (Nadler et al., 1995; Striem et al., 1996). HU-211 has been evaluated as a neuroprotectant in animal models of closed head injury, optic nerve crush, and global or focal ischemia. In these models, a single injection of HU-211 given after the insult conferred significant increases in neuronal survival. It is currently being evaluated in phase 1 clinical trials (Biegon, 1998, personal communication). The present invention is a new use for HU-211. The new use is to reduce brain damage resulting from seizures caused by organophosphorus nerve agents.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a method for reducing seizure-related brain damage caused by organophosphorus nerve agents.
This and other objects of the invention are achieved by a method of reducing brain damage resulting from seizures caused by an organophosphorus nerve agent comprising administering to a patient a therapeutically effective amount of HU-211.
In some embodiments, the organophosphorus nerve agent is one of GB (sarin), GD (soman), GA (tabun) and GF.
Preferably, the therapeutically effective amount of HU-211 is in the range of about 48 mg to about 200 mg per day.
Further objects, features and advantages of the invention will become apparent from the following detailed description taken in conjunction with the following drawing.
REFERENCES:
Filbert et al.; “Neuroprotective effects of HU-211 on brain damage resulting from soman-induced seizures”; Society for Neuroscience Abstracts, (1998) vol. 24, No. 1-2, pp. 1938. Meeting Info.: 28th Annual Meeting of the Society for Neuroscience, Part, 1998.*
Feigenbaum J., Bergmann F., Richmond S., Mechoulam R., Nadler V., Kloog Y. and Sokolovsky M. (1989) Nonpsychotropic cannabanoid acts as a functional N-methyl-D-aspartate receptor blocker.Proc. Natl. Acad. Sci. USA86, pp. 9584-9587.
Shohami E., Novikov M. and Mechoulam R. (1993) A Nonpsychotropic Cannaboid, HU-211, Has Cerebroprotective Effects After Closed Head Injury in the Rat.J of Neurotrauma10, pp. 109-119.
Nadler V., Mechoulam R. and Sokolovsky M. (1993) Blockade of45Ca2+influx through the N-methyl-D-asparate receptor ion channel by the non-psychoactive cannaboid HU-211.Brain Res622, pp. 79-85.
Streim S., Bar-Joseph A., Berkovitch Y. and Biegon A. (1997) Interaction of Dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system.Eur J Pharmacol338, pp. 205-213.
Belayev L., Busto R., Watson B. and Ginsberg M. (1995) Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-barrier disruption in photochemical cortical infarction in rats: a quantitative study.Brain Res702, pp. 266-270.
Shohami E., Novikov M.and Bass R. (1995) Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat.Brain Res674, pp. 55-62.
Nadler V., Biegon A, Beit-Yanni E., Adamchik J and Shohami E., (1995) Ca accumulation in rat brain after closed head injury: attenuation by the novel neuroprotective agent HU-211.Brain Res685, pp. 1-11.
Brewster M.E., Pop E., Foltz R.L., Reuschel S., Griffith W., Amselem S. and Beigon A., (1997) Clinical Pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers.Intl J of Clinical Pharmacol and Ther35, pp. 361-365.
Bar-Joseph A., Berkovitch Y., Adamchik J.and Biegon A., (1994) Neuroprotective Activity of HU-211, a Novel NMDA Antagonist, in Global Ischemia in Gerbils.Molecular and Chemical Neuropathology23, pp. 125-135.
Gallily R., Yamin A., Waksmann Y., Ovadia H., Weidenfeld J., Bar-Joseph A., Biegon A., Mechoulam R. and Shohami E. (1997) Protection Against Septic Shock and Suppression of Tumor Mecrosis Factor ∝ and Nitric Oxide Production by Dexanabinol (HU-211), a Nonpsychotropic Cannabinoid.J of Pharmacol and Exp Ther283, pp. 918-924.
Eshhar N., Striem S., Kohen R., Tirosh O. and Biegon A. (1995) Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist.Eur J Pharmacol283, pp. 19-29.
Eshhar N., Striem S. and Biegon A., (1993) HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture.NeuroReport5, pp. 237-240.
Biegon A., and Bar Joseph A. (1995) Development of HU211 as a neuroprotectant for ischemic brain damage.Neurol Res17, pp. 275-280.
Ballough Gerald Paul Harding
Filbert Margaret Gillespie
Arwine Elizabeth
Criares Theodore J.
Kim Jennifer
The United States of America as represented by the Secretary of
LandOfFree
Method of reducing brain damage resulting from seizures does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing brain damage resulting from seizures, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing brain damage resulting from seizures will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2502890